胰激肽原酶治疗高血压合并微量白蛋白尿的效果观察

Curative effect of pancreatic kininogenase in treatment of hypertension patients with microalbuminuria

目的探讨胰激肽原酶治疗高血压合并微量白蛋白尿(MAU)的临床疗效及安全性。方法收集2012年1月至2014年1月本院收治的高血压合并MAU患者78例,随机分为观察组与对照组,每组各39例。对照组患者予以高血压常规治疗,观察组患者在此基础上加用胰激肽原酶治疗,比较两组患者的治疗效果及不良反应发生情况。结果两组患者治疗后收缩压(SBP)及舒张压(DBP)均较治疗前显著降低(P<0.05),但组间比较无明显差异(P>0.05);治疗后观察组患者晨尿白蛋白/肌酐(A/C)比值、尿白蛋白排泄率(UAER)、MAU及血浆内皮素-1(ET-1)水平均显著低于对照组,血浆一氧化氮(NO)水平显著高于对照组,差异显著(P<0.05);观察组患者不良反应发生率为7.69%,与对照组(5.13%)比较无明显差异(P>0.05)。结论胰激肽原酶治疗高血压合并MAU,能够改善患者血管内皮功能,提高临床疗效,不良反应较少,安全可靠,值得临床推广应用。

Objective To investigate the clinical efficacy and safety of pancreatic kallikrein for the treatment of hypertension with microalbuminuria. Method 78 cases of hypertension patients with microalbuminuria in our hospital from January 2012 to January 2014 were collected and randomly divided into observation group and control group, 39 cases in each group. Control group received conventional treatment of hypertension, observation group received pancreatic kininogenase treatment on the basis of control group, the therapeutic effects and adverse reactions of two groups were compared. Result After treatment, the SBP and DBP of two groups were significantly decreased than before treatment（P〈0.05）, but had no significant difference between two groups（P〉0.05）; the morning urine A/C, UAER, MAU and plasma ET-1 in observation group were significantly lower than control group, and plasma NO level was significantly higher than control group（P〈0.05）; the adverse reactions rate of observation group was 7.69%, had no significant difference with control group（5.13%）（P〉0.05）. Conclusion Pancreatic kininogenase in treatment of hypertension with microalbuminuria can reduce albuminuria, improve endothelial function and clinical outcomes, with less adverse reaction, it is safe and reliable, should be widely applied.